PMID- 34109528
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20221207
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 190
IP  - 4
DP  - 2021 Nov
TI  - Evaluation of salusin-alpha and salusin-beta levels in patients with type 2 diabetes 
      mellitus and determination of the impact of severity of hyperglycemia on salusin 
      levels.
PG  - 1403-1411
LID - 10.1007/s11845-021-02674-4 [doi]
AB  - AIMS: To investigate the usefulness of salusin-alpha and salusin-beta as biomarkers in 
      patients with type 2 diabetes mellitus (T2DM) and to determine whether diabetes 
      severity and obesity have an effect on the salusin levels in diabetic patients. 
      METHODS: The study included a total of 90 patients, comprising 55 diagnosed with 
      T2DM and 35 healthy volunteers with similar demographic characteristics. Salusins 
      were assayed by a commercially available ELISA kit. RESULTS: The salusin-beta levels 
      were found to be significantly higher in T2DM group compared to control group, 
      while the salusin-alpha levels were lower (p < 0.05, for both). Furthermore, in 
      patient group, Spearman analysis showed a statistically significant negative 
      correlation between salusin-alpha and fasting glucose and glycated hemoglobin 
      (HbA1c), whereas salusin-beta had a statistically significant positive correlation 
      with fasting glucose and HbA1c (p < 0.05, for both). When analyzed according to 
      the HbA1c groups, the patients with HbA1c > 9% had significantly lower salusin-alpha 
      and higher salusin-beta levels levels compared to those with HbA1c < 9% (p < 0.05, 
      for both). When examined according to body-mass-index groups, there was no 
      significant difference in the salusin levels of the patient and control groups 
      (p > 0.05). CONCLUSION: We demonstrated that the serum salusin-alpha level was 
      decreased whereas the salusin-beta level was increased in patients with T2DM 
      compared to healthy subjects, and this was more pronounced as T2DM-deteriorated. 
      We also showed that obesity had no effect on salusin levels among diabetics. This 
      study may provide a basis for the availability of salusin-targeted therapies, 
      especially in uncontrolled T2DM.
CI  - (c) 2021. Royal Academy of Medicine in Ireland.
FAU - Argun, Derya
AU  - Argun D
AUID- ORCID: 0000-0002-0141-3515
AD  - Department of Internal Medicine, Istanbul Aydin University Medical Faculty, 
      Istanbul, Turkey. dr.deryaargun@gmail.com.
FAU - Argun, Ferit
AU  - Argun F
AUID- ORCID: 0000-0002-2192-9084
AD  - Department of Internal Medicine, Istanbul Aydin University Medical Faculty, 
      Istanbul, Turkey.
FAU - Borku Uysal, Betul
AU  - Borku Uysal B
AUID- ORCID: 0000-0001-9292-5024
AD  - Department of Internal Medicine, Biruni University Medical Faculty, Istanbul, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210609
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Biomarkers)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (TOR2A protein, human)
SB  - IM
MH  - Biomarkers
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Hyperglycemia
MH  - Intercellular Signaling Peptides and Proteins
OTO - NOTNLM
OT  - Endothelial dysfunction
OT  - Obesity
OT  - Salusin-alpha
OT  - Salusin-beta
OT  - Type 2 diabetes mellitus
EDAT- 2021/06/11 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/06/10 06:57
PHST- 2021/04/25 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/06/11 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/06/10 06:57 [entrez]
AID - 10.1007/s11845-021-02674-4 [pii]
AID - 10.1007/s11845-021-02674-4 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2021 Nov;190(4):1403-1411. doi: 10.1007/s11845-021-02674-4. Epub 
      2021 Jun 9.